Our study found that SLC26A4 is involved in cardiac hypertrophy and inhibiting SLC26A4 could decrease the release of ANP or BNP and promote the expression of GSK-3β in vivo and in vitro. Here, GSK3B is linked to cardiac hypertrophy.